Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2013 May;98(5):808-13.
doi: 10.3324/haematol.2012.070839. Epub 2012 Nov 9.

Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation--an International Primary Central Nervous System Lymphoma Study Group project

Jacoline E Bromberg  1 , Jeanette K Doorduijn, Gerald Illerhaus, Kristoph Jahnke, Agniezka Korfel, Lars Fischer, Kristina Fritsch, Outti Kuittinen, Samar Issa, Cees van Montfort, Martin J van den Bent
Affiliations
Multicenter Study

Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation--an International Primary Central Nervous System Lymphoma Study Group project

Jacoline E Bromberg et al. Haematologica. 2013 May.

Abstract

Autologous stem cell transplantation has greatly improved the prognosis of systemic recurrent non-Hodgkin's lymphoma. However, no prospective data are available concerning the feasibility and efficacy of this strategy for systemic lymphoma relapsing in the central nervous system. We, therefore, we performed an international multicenter retrospective study of patients with a central nervous system recurrence of systemic lymphoma to assess the outcome of these patients in the era of stem cell transplantation. We collected clinical and treatment data on patients with a first central nervous system recurrence of systemic lymphoma treated between 2000 and 2010 in one of five centers in four countries. Patient- and treatment-related factors were analyzed and compared descriptively. Primary outcome measures were overall survival and percentage of patients transplanted. We identified 92 patients, with a median age of 59 years and a median Eastern Cooperative Oncology Group/World Health Organization performance status of 2, of whom 76% had diffuse large B-cell histology. The majority (79%) of these patients were treated with systemic chemotherapy with or without intravenous rituximab. Twenty-seven patients (29%) were transplanted; age and insufficient response to induction chemotherapy were the main reasons for not being transplanted in the remaining 65 patients. The median overall survival was 7 months (95% confidence interval 2.6-11.4), being 8 months (95% confidence interval 3.8-5.2) for patients ≤ 65 years old. The 1-year survival rate was 34.8%; of the 27 transplanted patients 62% survived more than 1 year. The Memorial Sloan Kettering Prognostic Index for primary central nervous system lymphoma was prognostic for both undergoing transplantation and survival. In conclusion, despite the availability of autologous stem cell transplantation for patients with central nervous system progression or relapse of systemic lymphoma, prognosis is still poor. Long-term survival is, however, possible and more likely in patients able to undergo stem cell transplantation.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
(A) Overall survival (in months) by age. (B) Overall survival (in months) by performance status. (C) Overall survival (in months) by MSKCC prognostic score. (D) Overall survival (in months) by stem cell transplantation.
See this image and copyright information in PMC

Comment in

References

    1. Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOV-ER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood. 2009;113(17):3896–902 - PubMed
    1. Bollen EL, Brouwer RE, Hamers S, Hermans J, Kluin M, Sankatsing SU, et al. Central nervous system relapse in non-Hodgkin lymphoma. A single-center study of 532 patients. Arch Neurol. 1997;54(7): 854–9 - PubMed
    1. Bjorkholm M, Hagberg H, Holte H, Kvaloy S, Teerenhovi L, Anderson H, et al. Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up. Ann Oncol. 2007; 18(6):1085–9 - PubMed
    1. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995; 333(23):1540–5 - PubMed
    1. Gribben JG, Goldstone AH, Linch DC, Taghipour G, Mcmillan AK, Souhami RL, et al. Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin’s lymphomas who are still responsive to conventional-dose therapy. J Clin Oncol. 1989;7(11):1621–9 - PubMed

Publication types

MeSH terms